Taysha Gene Therapies, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q4 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Taysha Gene Therapies, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q4 2019 to Q3 2024.
  • Taysha Gene Therapies, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$25.5M, a 78.2% increase year-over-year.
  • Taysha Gene Therapies, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$22.8M, a 89.4% increase year-over-year.
  • Taysha Gene Therapies, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$112M, a 32.8% increase from 2022.
  • Taysha Gene Therapies, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$166M, a 4.88% increase from 2021.
  • Taysha Gene Therapies, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$175M, a 191% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$22.8M -$25.5M +$91.6M +78.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$114M -$20.9M +$3.67M +14.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 -$118M -$24.1M -$6.44M -36.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$112M $47.7M +$103M Oct 1, 2023 Dec 31, 2023 10-K 2024-03-19
Q3 2023 -$214M -$117M -$90.6M -341% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$124M -$24.6M +$9.49M +27.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 -$133M -$17.6M +$32.7M +65% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$166M -$55.1M -$4.69M -9.31% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-19
Q3 2022 -$161M -$26.5M +$24.7M +48.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$186M -$34.1M +$6.83M +16.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$193M -$50.3M -$18.3M -57.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$175M -$50.4M -$32.1M -175% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-28
Q3 2021 -$142M -$51.2M -$36.1M -240% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$106M -$40.9M -$19.7M -92.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$86.6M -$32M -$26.6M -490% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$60M -$18.3M -$17.2M -1543% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$42.8M -$15M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$21.2M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 -$5.43M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q4 2019 -$1.12M Sep 21, 2019 Dec 31, 2019 10-K 2021-03-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.